TY - JOUR T1 - Bevacizumab (Avastin) JF - American Journal of Neuroradiology JO - Am. J. Neuroradiol. SP - 235 LP - 236 DO - 10.3174/ajnr.A1987 VL - 31 IS - 2 AU - S.K. Mukherji Y1 - 2010/02/01 UR - http://www.ajnr.org/content/31/2/235.abstract N2 - SUMMARY: Bevacizumab is a humanized monoclonal antibody that was the first FDA approved therapy designed to inhibit angiogenesis. This paper will review the mechanism of action and clinical role of this antiangiogenic agent. FDAU.S. Food and Drug AdministrationVEGFvascular endothelial growth factor ER -